eligibility_summary
Eligible: unresectable, platinum‑resistant advanced ovarian cancer with mesothelin IHC ≥26% (fresh biopsy or recent FFPE), prior platinum failed, measurable disease, ECOG 0–1, >3‑mo survival, adequate cardiac/renal/hepatic/hematologic function, recovered toxicities, consent, venous access. Exclude: recent other cancers, active HBV/HCV/HIV/syphilis, CNS mets, recent live vaccine, severe allergy, uncontrolled CV/QTc, serious illness/infection/autoimmune (except vitiligo), immunosuppression, recent anticancer therapy, pregnancy, prior cell/gene therapy, poor compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: TCR-like CAR-T (biologic, autologous gene‑modified T‑cell therapy). Patients’ T cells are engineered to express a chimeric antigen receptor that targets mesothelin (MSLN) on ovarian cancer cells. Mechanism: CAR engagement of MSLN triggers T‑cell activation via CD3ζ/costimulatory signaling, leading to immune synapse formation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing of tumor cells. Dosing: single IV infusion in dose‑escalation cohorts (1×10^6, 3×10^6, 1×10^7, 2×10^7 cells/kg). Targets: MSLN‑positive ovarian cancer cells, T‑cell activation pathways within infused CAR‑T cells. Objective: evaluate safety and preliminary efficacy in advanced, platinum‑resistant, MSLN‑positive ovarian cancer.